The study aimed to establish the impact of age on the predictive capability of ferritin, ferritin-hemoglobin ratio (FHR), IL-6, and sIL-2R in COVID-19 patients. Compared to patients with moderate condition, patients with severe condition had higher ferritin level (441.0 [188.0-829.8] ng/mL vs 281.0 [172.0-388.0] ng/mL, p = 0.002), sIL-2R level (6.0 [4.7-9.0] pg/mL vs 5.3 [3.7-6.9] pg/mL, p = 0.020), FHR (38.4 [15.1-63.4] vs 22.0 [12.1-32.1], p = 0.002). The area under the curves (AUC) for discriminative capabilities of the following biomarkers for severe condition were assessed in patients aged <65 years and patients aged ≥65 years: ferritin (AUC = 0.585, p = 0.309 vs AUC = 0.683, p = 0.002), FHR (AUC = 0.589, p = 0.302 vs AUC = 0.688, p = 0.002), IL-6 (AUC = 0.503, p = 0.972 vs AUC = 0.647, p = 0.019), and sIL-2R (AUC = 0.549, p = 0.552 vs AUC = 0.646, p = 0.017). Also AUCs for discriminative capabilities for in-hospital mortality were compared in patients aged <65 years and ≥65 years: ferritin (AUC = 0.607, p = 0.628 vs AUC = 0.661, p = 0.105), FHR (AUC = 0.612, p = 0.621 vs AUC = 0.688, p = 0.002), IL-6 (AUC = 0.580, p = 0.724 vs AUC = 0.695, p = 0.016), and sIL-2R (AUC = 0.620, p = 0.491 vs AUC = 0.695, p = 0.029). Thus, ferritin, FHR, IL-6, and sIL-2R didn't show acceptable predictive value for severe condition and lethal outcome in patients aged <65 years but had high predictive value for lethal outcome in patients aged ≥65 years.

• MeSH
• Biomarkers * blood   MeSH
• COVID-19 * mortality   blood   MeSH
• Ferritins * blood   MeSH
• Hemoglobins analysis   metabolism   MeSH
• Interleukin-6 * blood   MeSH
• Middle Aged MeSH
• Humans MeSH
• Predictive Value of Tests MeSH
• Receptors, Interleukin-2 blood   MeSH
• SARS-CoV-2 MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Severity of Illness Index * MeSH
• Age Factors MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

Cílem post hoc analýzy studie ASPREE bylo zjistit vliv nízkých dávek kyseliny acetylsalicylové (ASA) na anémii, koncentraci hemoglobinu a sérového feritinu. Studie prokázala, že nízké dávky ASA zvyšují výskyt anémie a působí pokles koncentrace feritinu u jinak zdravých starších dospělých nezávisle na závažném krvácení. U starších osob užívajících ASA je třeba zvážit pravidelné monitorování koncentrace hemoglobinu.

The aim of the post hoc analysis of data obtained in the ASPREE trial was to evaluate the impact of low‐dose acetylsalicylic acid (ASA) on the development of anemia, hemoglobin concentration, and serum ferritin levels. The trial showed that low‐dose ASA increased the risk of anemia and caused hemoglobin concentration decrease in otherwise healthy senior adults independently of the occurrence of serious bleeding. Regular hemoglobin concentration monitoring should be contemplated in senior patients treated with ASA.

• Keywords
• studie ASPREE,
• MeSH
• Anemia * diagnosis   etiology   MeSH
• Aspirin * administration & dosage   therapeutic use   MeSH
• Ferritins analysis   blood   MeSH
• Hemoglobins analysis   MeSH
• Humans MeSH
• Randomized Controlled Trials as Topic MeSH
• Aged MeSH
• Check Tag
• Humans MeSH
• Aged MeSH

Léčba karboxymaltózou železa (FCM) zmírňuje příznaky a zlepšuje kvalitu života u pacientů se srdečním selháním se sníženou ejekční frakcí levé komory (EF LK) a nedostatkem železa. Studie HEART‐FID byla zaměřena na další důkazy o vlivu FCM na klinické příhody. Její výsledky doložily, že u pacientů trpících srdečním selháním se sníženou EF LK a nedostatkem železa nebyl patrný rozdíl mezi skupinami s FCM a s placebem s ohledem na složený primární cílový ukazatel − úmrtí, hospitalizace pro srdeční selhání nebo změna vzdálenosti v šestiminutovém testu chůzí.

The treatment with ferric carboxymaltose (FCM) alleviates the symptoms and improves the quality of life in patients suffering from heart failure with reduced left ventricular ejection fraction (HFrEF) and iron deficiency. The HEART‐FID study dealt with new data concerning the relationship between FCM use and clinical events. As for the composite primary endpoint (comprising deaths, hospitalizations for HF and changes in a 6 minute walk test), this study showed that FCM compared to placebo did not improve outcomes in patients with HFrEF and iron deficiency.

• Keywords
• studie HEART-FID, karboxymaltóza železa,
• MeSH
• Iron Deficiencies * drug therapy   prevention & control   MeSH
• Adult MeSH
• Ferritins analysis   blood   MeSH
• Clinical Studies as Topic MeSH
• Humans MeSH
• Iron Compounds pharmacology   classification   therapeutic use   MeSH
• Heart Failure, Systolic * diagnosis   drug therapy   mortality   MeSH
• Walk Test classification   methods   MeSH
• Check Tag
• Adult MeSH
• Humans MeSH

BACKGROUND: Data on the clinical significance of iron deficiency (ID) in patients with myocardial infarction (MI) are conflicting. This may be related to the use of various ID criteria. We aimed to compare the association of different ID criteria with all-cause mortality after MI. METHODS: Consecutive patients hospitalized for their first MI at a large tertiary heart center were included. We evaluated the association of different iron metabolism parameters measured on the first day after hospital admission with all-cause mortality. RESULTS: From the 1,156 patients included (aged 64±12 years, 25 % women), 194 (16.8 %) patients died during the median follow-up of 3.4 years. After multivariate adjustment, iron level ≤13 μmol/L (HR 1.67, 95 % CI 1.19-2.34) and the combination of iron level ≤12.8 μmol/L and soluble transferrin receptor (sTfR) ≥3 mg/L (HR 2.56, 95 % CI 1.64-3.99) termed as PragueID criteria were associated with increased mortality risk and had additional predictive value to the GRACE score. Compared to the model including iron level, the addition of sTfR improved risk stratification (net reclassification improvement 0.61, 95 % CI 0.52-0.69) by reclassifying patients into a higher-risk group. No association between ferritin level and mortality was found. 51 % of patients had low iron levels, and 58 % fulfilled the PragueID criteria. CONCLUSION: Iron deficiency is common among patients with the first MI. The PragueID criteria based on iron and soluble transferrin receptor levels provide the best prediction of mortality and should be evaluated in future interventional studies for the identification of patients potentially benefiting from intravenous iron therapy.

• MeSH
• Anemia, Iron-Deficiency * mortality   MeSH
• Iron Deficiencies MeSH
• Ferritins blood   MeSH
• Hospitalization MeSH
• Myocardial Infarction * mortality   MeSH
• Middle Aged MeSH
• Humans MeSH
• Multivariate Analysis MeSH
• Cause of Death MeSH
• Proportional Hazards Models MeSH
• Receptors, Transferrin blood   MeSH
• Risk Factors MeSH
• Aged MeSH
• Iron * blood   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

Susceptibility to COVID-19, the most devastating global pandemic, appears to vary widely across different population groups. Exposure to toxoplasmosis has been proposed as a theory to explain the diversity of these populations. The aim of the present study was to investigate the possible association between latent toxoplasmosis and COVID-19 and its probable correlation with markers of oxidative stress, C-reactive protein (CRP) and ferritin. In a case-control study, blood samples were collected from 91 confirmed (48 non-pneumonic; NP, and 43 pneumonic; P) COVID-19 patients and 45 healthy controls. All participants were tested for IgG anti-Toxoplasma gondii antibodies and oxidative stress markers (nitric oxide [NO], superoxide dismutase [SOD] and reduced glutathione [GSH]), and CRP and serum ferritin levels were determined. In COVID-19 patients, IgG anti-T. gondii antibodies were found in 54% compared to 7% in the control group, with the difference being statistically significant (P ˂ 0.001). However, no significant correlation was found between the severity of COVID-19 and latent T. gondii infection. Latent toxoplasmosis had a strong influence on the risk of COVID-19. NO and SOD levels were significantly increased in COVID-19 patients, while GSH levels decreased significantly in them compared to control subjects (P ˂ 0.001 for both values). CRP and ferritin levels were also significantly elevated in P COVID-19 patients infected with toxoplasmosis. This is the first study to look at the importance of oxidative stress indicators in co-infection between COVID-19 and T. gondii. The high prevalence of latent toxoplasmosis in COVID-19 suggests that T. gondii infection can be considered a strong indicator of the high risk of COVID-19.

• MeSH
• Biomarkers MeSH
• COVID-19 * MeSH
• Ferritins MeSH
• Immunoglobulin G MeSH
• Humans MeSH
• Nitric Oxide MeSH
• Oxidative Stress MeSH
• Antibodies, Protozoan MeSH
• Risk Factors MeSH
• Seroepidemiologic Studies MeSH
• Case-Control Studies MeSH
• Superoxide Dismutase MeSH
• Toxoplasmosis * epidemiology   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH

• Keywords
• karboxymaltóza železa,
• MeSH
• Home Infusion Therapy MeSH
• Iron Deficiencies diagnosis   etiology   MeSH
• Ferritins analysis   blood   drug effects   MeSH
• Comorbidity MeSH
• Humans MeSH
• Maltose administration & dosage   therapeutic use   MeSH
• Heart Failure * etiology   physiopathology   therapy   MeSH
• Webcasts as Topic MeSH
• Ferric Compounds administration & dosage   therapeutic use   MeSH
• Iron metabolism   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Newspaper Article MeSH

BACKGROUND: Iron deficiency in athletes is initially treated with a nutritional intervention. If negative iron balance persists, oral iron supplementation (OIS) can be used. Despite the recent proposal for a refinement of treatment strategies for iron-deficient athletes, there is no general consensus regarding the actual efficiency, dosage, or optimal regimen of OIS. OBJECTIVE: The aim of this meta-analysis was to evaluate to what extent OIS affects blood iron parameters and physical performance in healthy adult athletes. METHODS: PubMed, Web of Science, PEDro, CINAHL, SPORTDiscus, and Cochrane were searched from inception to 2 November 2022. Articles were eligible if they satisfied the following criteria: recruited subjects were healthy, adult and physically active individuals, who used exclusively OIS, irrespective of sex and sports discipline. EXCLUSION CRITERIA: simultaneous supplementation with iron and any other micronutrient(s), intravenous iron supplementation or recent exposure to altitude acclimatisation. The methodological quality of included studies was assessed with the PEDro scale, the completeness of intervention reporting with the TIDieR scale, while the GRADE scale was used for quality of evidence synthesis. The present study was prospectively registered in PROSPERO online registry (ID: CRD42022330230). RESULTS: From 638 articles identified through the search, 13 studies (n = 449) were included in the quantitative synthesis. When compared to the control group, the results demonstrated that OIS increases serum ferritin (standardized mean difference (SMD) = 1.27, 95% CI 0.44-2.10, p = 0.006), whereas blood haemoglobin (SMD = 1.31, 95% CI - 0.29 to 2.93, p = 0.099), serum transferrin receptor concentration (SMD = - 0.74, 95% CI - 1.89 to 0.41, p = 0.133), and transferrin saturation (SMD = 0.69, 95% CI - 0.84 to 2.22, p = 0.330) remained unaltered. Following OIS, a trend of small positive effect on VO2max (SMD = 0.49, 95% CI - 0.09 to 1.07, p = 0.086) was observed in young healthy athletes. The quality of evidence for all outcomes ranged from moderate to low. CONCLUSIONS: Increase in serum ferritin concentration after OIS was evident in subjects with initial pre-supplementation serum ferritin concentration ≤ 12 μg/l, while only minimal, if any effect, was observed in subjects with higher pre-supplementation serum ferritin concentration. The doses of OIS, that induced a beneficial effect on hematological parameters differed from 16 to 100 mg of elementary iron daily, over the period between 6 and 8 weeks. Shorter supplementation protocols have been shown to be ineffective.

• MeSH
• Anemia, Iron-Deficiency drug therapy   blood   MeSH
• Administration, Oral MeSH
• Ferritins blood   MeSH
• Hemoglobins analysis   metabolism   MeSH
• Humans MeSH
• Dietary Supplements * MeSH
• Randomized Controlled Trials as Topic * MeSH
• Athletes MeSH
• Athletic Performance physiology   MeSH
• Iron * administration & dosage   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Meta-Analysis MeSH
• Systematic Review MeSH

Souhrn: Hereditární hemochromatóza patří mezi onemocnění, při kterých se nadměrně hromadí železo v těle, a patří mezi nejčastější vrozená metabolická onemocnění. Kazuistika prezentuje případ pacienta s akutním krvácením do horní části gastrointestinálního traktu, se zvýšenou hodnotou sérového železa a feritinu, bez elevace bilirubinu, transamináz nebo obstrukčních jaterních testů, u něhož byla dalším došetřením zjištěna genetická hemochromatóza.

Summary: Hereditary hemochromatosis is a disease in which iron accumulates excessively in the body and it is one of the most common congenital metabolic diseases. The case report presents a patient from practice with acute upper gastrointestinal bleeding, with increased serum iron and ferritin values, without elevation in bilirubin, transaminases or obstructive liver tests, in whom further examination revealed genetic hemochromatosis.

• MeSH
• Cytapheresis methods   MeSH
• Diagnosis, Differential MeSH
• Erythrocytes MeSH
• Ferritins analysis   blood   MeSH
• Gastrointestinal Hemorrhage diagnosis   etiology   drug therapy   MeSH
• Hemochromatosis * diagnosis   genetics   MeSH
• Middle Aged MeSH
• Humans MeSH
• Mutation MeSH
• Hemochromatosis Protein genetics   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Publication type
• Case Reports MeSH

• MeSH
• Diet Therapy MeSH
• Elasticity Imaging Techniques methods   MeSH
• Ferritins analysis   MeSH
• Sodium-Glucose Transporter 2 Inhibitors pharmacology   therapeutic use   MeSH
• Humans MeSH
• Metabolic Syndrome complications   MeSH
• Metformin pharmacology   therapeutic use   MeSH
• Non-alcoholic Fatty Liver Disease * diagnosis   drug therapy   prevention & control   MeSH
• Obesity complications   MeSH
• Check Tag
• Humans MeSH

In this study we use comparative genomics to uncover a gene with uncharacterized function (1700011H14Rik/C14orf105/CCDC198), which we hereby name FAME (Factor Associated with Metabolism and Energy). We observe that FAME shows an unusually high evolutionary divergence in birds and mammals. Through the comparison of single nucleotide polymorphisms, we identify gene flow of FAME from Neandertals into modern humans. We conduct knockout experiments on animals and observe altered body weight and decreased energy expenditure in Fame knockout animals, corresponding to genome-wide association studies linking FAME with higher body mass index in humans. Gene expression and subcellular localization analyses reveal that FAME is a membrane-bound protein enriched in the kidneys. Although the gene knockout results in structurally normal kidneys, we detect higher albumin in urine and lowered ferritin in the blood. Through experimental validation, we confirm interactions between FAME and ferritin and show co-localization in vesicular and plasma membranes.

• MeSH
• Genome-Wide Association Study * MeSH
• Energy Metabolism * genetics   MeSH
• Ferritins genetics   MeSH
• Kidney MeSH
• Humans MeSH
• Neanderthals MeSH
• Body Weight MeSH
• Animals MeSH
• Check Tag
• Humans MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH